Screening performance of first-trimester nuchal translucency for major cardiac defects: A meta-analysis

American Journal of Obstetrics and Gynecology

Volumn 189, Issue 5, 2003, Pages 1330-1335

  Makrydimas, George ^a   Sotiriadis, Alexandros ^a   Ioannidis, John P A ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Cardiac defect; Meta analysis; Nuchal translucency

Indexed keywords

ARTICLE; CONGENITAL HEART MALFORMATION; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY;

EID: 0346751039     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0002-9378(03)00645-8     Document Type: Article

References (25)

1. Hoffman JI. Congenital heart disease: incidence and inheritance. Pediatr Clin North Am 1990;37:25-43.
2. Yang Q, Khoury M, Mannino D. Trends and patterns of mortality associated with birth defects and genetic diseases in the United States, 1979-1992: an analysis of multiple-cause morbidity data. Available from: http:/www.cdc.gov/ genomics/info/reports/files/ print/trends.pdf (Update 03-07-2002).
3. Buskens E, Grobbee DE, Frohn-Mulder IM, Stewart PA, Juttmann RE, Wladimiroff JW, et al. Efficacy of routine fetal ultrasound screening for congenital heart disease in normal pregnancy. Circulation 1996;94:67-72.
4. Achiron R, Glaser J, Gelernter I, Hegesh J, Yagel S. Extended fetal echocardiographic examination for detecting cardiac malformations in low risk pregnancies. BMJ 1992;304:671-4.
5. Stümpflen I, Stümpflen A, Wimmer M, Bernaschek G. Effect of detailed fetal echocardiography as part of routine prenatal ultrasonographic screening on detection of congenital heart disease. Lancet 1996;348:854-7.
6. Allan LD. Echocardiographic detection of congenital heart disease in the fetus: present and future. Br Heart J 1995;74:103-6.
7. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231-7.
8. Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ 1999;318:81-5.
9. Pandya PP, Snijders RJM, Johnson SP, Brizot ML, Nikolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. BJOG 1995;102:957-62.
10. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993; 12:1293-316.
11. Bilardo CM, Pajkrt E, de Graaf I, Mol BW, Bleker OP. Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound Obstet Gynecol 1998;11:401-6.
12. Brady AF, Pandya PP, Yuksel B, Greenough A, Patton MA, Nicolaides KH. Outcome of chromosomally normal livebirths with increased fetal nuchal translucency at 10-14 weeks' gestation. J Med Genet 1998;35:222-4.
13. Pajkrt E, van Lith JM, Mol BW, Bleker OP, Bilardo CM. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population. Ultrasound Obstet Gynecol 1998; 12:163-9.
14. Hafner E, Schuchter K, Liebhart E, Philipp K. Results of routine fetal nuchal translucency measurement at weeks 10-13 in 4233 unselected pregnant women. Prenat Diagn 1998;18:29-34.
15. Josefsson A, Molander E, Selbing A. Nuchal translucency as a screening test for chromosomal abnormalities in a routine first trimester ultrasound examination. Acta Obstet Gynecol Scand 1998;77:497-9.
16. Schwärzler P, Carvalho JS, Senat M-V, Masroor T, Campbell S, Ville Y. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population. BJOG 1999;106:1029-34.
17. Simpson JM, Sharland GK. Nuchal translucency and congenital heart defects: Heart failure or not? Ultrasound Obstet Gynecol 2000;16: 30-6.
18. Michailidis GD, Economides DL. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 2001;17:102-5.
19. Mavrides E, Cobian-Sanchez F, Tekay A, Moscoso G, Campbell S, Thilaganathan B, et al. Limitations using first-trimester nuchal translucency in routine screening for major congenital heart defects. Ultrasound Obstet Gynecol 2001;17:106-10.
20. Orvos H, Wayda K, Kozinsky Z, Katona M, Pál A, Szabó J. Increased nuchal translucency and congenital heart defects in euploid fetuses: the Szeged experience. Eur J Obstet Gynecol Reprod Biol 2002;101: 124-8.
21. Tegnander E, Eik-Ness SH, Johansen OJ, Linker DT. Prenatal detection of heart defects at the routine fetal examination at 18 weeks in a non-selected population. Ultrasound Obstet Gynecol 1995;5:372-80.
22. Benacerraf BR, Pober BR, Sanders SP. Accuracy of fetal echocardiography. Radiology 1987;165:847-9.
23. Roberts T, Henderson J, Mugford M, Bricker L, Neilson J, Garcia J. Antenatal ultrasound screening for fetal abnormalities: a systematic review of studies of cost and cost effectiveness. BJOG 2002;109:44-56.
24. Garson A Jr, Allen HD, Gersony WM, Gillette PC, Hohn AR, Pinsky WW, et al. The cost of congenital heart disease in children and adults: a model for assessment of price and practice variation. Arch Pediatr Adolesc Med 1994;148:1039-45.
25. Simpson JM, Jones A, Callaghan N, Sharland GK. Accuracy and limitations of transabdominal fetal echocardiography at 12-15 weeks of gestation in a population at high risk for congenital heart disease. BJOG 2000;107:1492-7.